Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COGNITIV AD: Encenicline in Mild to Moderate Alzheimer's Disease
NCT01969123Phase 3Terminated
- Sponsor
- FORUM Pharmaceuticals
- Start
- Oct 2013
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of encenicline in Alzheimer's disease (AD), sponsored by FORUM Pharmaceuticals. Started Oct 2013; status: terminated.
02
Drugs
encenicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01969123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01969123.